Sumit Aggarwal
Known title: PRESIDENT AND CEOCIK: 0001854362
Associated companies
Transaction History
| ELOX | ▲ Buy | Option Exercise | 260,946 | $39K | 2/28/2026 | View on chart |
| ELOX | ▲ Buy | Option Exercise | 15,000 | — | 1/24/2026 | View on chart |
| ELOX | ▲ Buy | Grant | 1,000,000 | $0 | 9/19/2025 | View on chart |
| ELOX | ▲ Buy | Option Exercise | 196,880 | $20 | 8/14/2025 | View on chart |
| ELOX | ▲ Buy | Option Exercise | 30,000 | $0 | 1/24/2025 | View on chart |
| ELOX | ▲ Buy | Grant | 165,000 | $0 | 10/16/2024 | View on chart |
| ELOX | ▲ Buy | Option Exercise | 279,158 | $0 | 12/1/2021 | View on chart |
| ELOX | ▼ Sell | Tax Withholding | 81,933 | $59K | 12/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Eloxx Pharmaceuticals Included in Pre-Market Movers List
Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.
Eloxx Pharmaceuticals Included in Pre-Market Movers List. Eloxx Pharmaceuticals was featured in a recent roundup of healthcare stocks showing movement during Monday's pre-market session. The company currently trades with a low trailing P/E ratio of 5.3, which is significantly below the average analyst target price of $38.25. This inclusion highlights current market attention on the stock, though the specific drivers for the pre-market activity are not detailed in the provided report.